| Literature DB >> 33593217 |
Abstract
INTRODUCTION: Management of nontuberculous mycobacterial lung disease (NTM-LD) can be encumbered by difficult diagnostic criteria and complex treatment decisions. As prevalence of this debilitating, often refractory, progressive lung disease increases globally, management must evolve beyond antimicrobials to encompass holistic and customized treatments coordinated by practitioners across various specialties. AREAS COVERED: This review aims to complement the recently updated NTM-LD treatment guidelines and expand current approaches to diagnosis, treatment, and disease management in a multidisciplinary dimension. The foundation of effective long-term management of NTM-LD is awareness of diagnostic criteria, individual patient risk factors, and the importance of managing underlying pulmonary and nonpulmonary comorbidities. The value of adopting all available pharmacological and nonpharmacological treatment modalities with a patient-centered approach to address the needs of long-term patient care cannot be minimized. EXPERT OPINION: This section, while acknowledging the limited advances in understanding of NTM-LD and the availability of newer diagnostic and therapeutic tools over the last decade, underscores the need for a programmatic approach to this chronic, debilitating pulmonary infection. This will not only lead to more comprehensive patient care with better outcomes, but will also inspire and activate robust networks of research and public health initiatives in this field.Entities:
Keywords: Bronchiectasis; Mycobacterium abscessus; Mycobacterium avium complex; Mycobacterium kansasii; Mycobacterium xenopi; diagnosis; infection; multidisciplinary management; nontuberculous mycobacteria–lung disease; nontuberculous mycobacteria–pulmonary disease
Year: 2021 PMID: 33593217 DOI: 10.1080/17476348.2021.1887734
Source DB: PubMed Journal: Expert Rev Respir Med ISSN: 1747-6348 Impact factor: 3.772